NCT07414277Recruiting
CGM for Insulin-Treated T2DM During Post-Discharge Transition
Effects of Continuous Glucose Monitoring on Patients With Type 2 Diabetes Treated With Insulin During Post-Discharge Transition: A Multicenter Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 24 Jun 2026
Brief summary (registry, in English)
The transition from inpatient care to the home setting is a critical phase for glycemic management, often associated with decreased adherence and deterioration of glycemic control. This multicenter, randomized, open-label, controlled trial aims to evaluate the efficacy of Real-Time Continuous Glucose Monitoring (RT-CGM) versus Self-Monitoring of Blood Glucose (SMBG) in patients with Type 2 Diabetes Mellitus (T2DM) treated with insulin during the post-discharge transitional period. A total of 160 eligible participants will be randomized in a 1:1 ratio to either the RT-CGM group or the SMBG group. Participants will wear RT-CGM intermittently (every 4 weeks) or perform SMBG for the 12-week intervention period. They will also visit the clinic at Week 12 and Week 24 for follow-up assessments.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 160 (estimated)
- First submitted
- 9 Feb 2026
- Start date
- 11 May 2026
- Primary completion date
- 30 Sept 2027
- Lead sponsor
- Shanghai 6th People's Hospital
- Diseases
- Type 2 diabetes
- NCT number
- NCT07414277
What you commit to
- Study type: Interventional
- Planned participants: 160
- From 11 May 2026 to the primary completion date, 30 Sept 2027
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current use of oral corticosteroid therapy, or anticipated use during the trial period.
Other illness
- Severe skin disease at the sensor insertion site, or allergy to adhesive tape/adhesives.
- Any condition that, in the investigator's opinion, makes the participant unsuitable for the trial, for example: history of ocular trauma or other diagnosed eye diseases causing visual impairment; unwillingness to participate or inability to adequately understand/comply due to speech/language impairment; or presence of psychiatric disorders.
Lab values
- Current use of a real-time continuous glucose monitoring (RT-CGM) device, or use within the 3 months prior to enrollment.
- Severe liver disease, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>3 times the upper limit of normal (ULN).
- Severe renal impairment or end-stage renal disease, defined as estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m².
Other
- Pregnant women; positive pregnancy test at screening; or planning pregnancy during the study period.
- Currently participating in, or planning to participate in, another clinical trial.
Who the study is looking for
- Age 18 to 80 years (inclusive).
- Confirmed diagnosis of type 2 diabetes mellitus (T2DM).
- HbA1c between 8.0% and 13.0% (inclusive) within the last 1 month prior to screening/enrollment.
- Planned to receive insulin therapy for at least 6 months after hospital discharge, as assessed/confirmed by the treating physician (principal physician).
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shanghai General Hospital Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
| Shanghai 6th People's Hospital Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
| Shanghai 7th People's Hospital Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
| Shanghai Fengxian District Central Hospital Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.